The global cancer biomarkers market size was valued at USD 38.14 billion in 2024. The market is projected to grow from USD 42.87 billion in 2025 to USD 74.62 billion by 2032, exhibiting a CAGR of 8.2% during the forecast period. North America dominated the cancer biomarkers market with a 35.99% share in 2024, supported by advanced diagnostic infrastructure, strong research funding, and the rising adoption of personalized medicine in oncology care.